Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 135Small Cell Lung Carcinoma 51Lung Neoplasms 45Melanoma 15Carcinoma, Renal Cell 14Carcinoma, Transitional Cell 10Stomach Neoplasms 9Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Hepatocellular 9Mesothelioma, Malignant 8Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Neoplasm Metastasis 5Kidney Neoplasms 5Carcinoma, Merkel Cell 5Thoracic Neoplasms 4Carcinoma, Neuroendocrine 4Small Cell Lung Cancer Extensive Stage 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Mesothelioma 3Lung Diseases 3Gastrointestinal Neoplasms 3Esophageal Neoplasms 3Brain Neoplasms 3

Interventions

pembrolizumab 4fludarabine 2atezolizumab 2Nivolumab 2Cyclophosphamide 2fludarabine phosphate 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Microsatellite Instability × atezolizumab × Thoracic × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡